Biotech · Public company · Boston, MA, US
Rhythm Pharmaceuticals, Inc.
Ticker RYTM · SEC CIK 0001649904
Track this companyFree. Adds Rhythm Pharmaceuticals, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials245 recruiting or active
Pipeline programs23From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline23
- SetmelanotidePhase 3 · Hypothalamic ObesityClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 3 · Pro-opiomelanocortin (POMC) Deficiency ObesityClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 3 · Obesity Associated With Defects in Leptin-melanocortin PathwayClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 3 · ObesityClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 3 · Bardet-Biedl SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 3 · Bardet Biedl Syndrome (BBS)ClinicalTrials.gov · fetched Nov 12, 2026
- Setmelanotide 2 mgPhase 3 · Bardet-Biedl SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Setmelanotide 2.5 mgPhase 3 · Bardet-Biedl SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Setmelanotide 20 mgPhase 3 · Bardet-Biedl SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Setmelanotide 25 mgPhase 3 · Bardet-Biedl SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Setmelanotide 3 mgPhase 3 · Bardet-Biedl SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- Setmelanotide 30 mgPhase 3 · Bardet-Biedl SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- BivamelagonPhase 2 · Hypothalamic ObesityClinicalTrials.gov · fetched Nov 12, 2026
- Part C: RM-718Phase 2 · Hypothalamic ObesityClinicalTrials.gov · fetched Nov 12, 2026
- Part D: RM-718Phase 2 · Hypothalamic ObesityClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 2 · Genetic ObesityClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 2 · Prader-Willi SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 2 · HypertriglyceridemiaClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 2 · OverweightClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 2 · Overweight and ObesityClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotidePhase 1 · Renal InsufficiencyClinicalTrials.gov · fetched Nov 12, 2026
- MoxifloxacinHealthyClinicalTrials.gov · fetched Nov 12, 2026
- SetmelanotideHealthyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials24
- A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)PHASE2 · ENROLLING_BY_INVITATION · started Nov 10, 2025ClinicalTrials.gov NCT07156578 · fetched Nov 12, 2026
- A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)PHASE3 · RECRUITING · started Sep 23, 2025ClinicalTrials.gov NCT06760546 · fetched Nov 12, 2026
- A Study of Setmelanotide in Patients With Prader-Willi SyndromePHASE2 · ACTIVE_NOT_RECRUITING · started Mar 4, 2025ClinicalTrials.gov NCT06772597 · fetched Nov 12, 2026
- Open-Label Extension Study of SetmelanotidePHASE3 · COMPLETED · started Oct 21, 2024ClinicalTrials.gov NCT06596135 · fetched Nov 12, 2026
- A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityPHASE2 · COMPLETED · started Jul 11, 2024ClinicalTrials.gov NCT06046443 · fetched Nov 12, 2026
- A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Mar 5, 2024ClinicalTrials.gov NCT06239116 · fetched Nov 12, 2026
- A Trial of Setmelanotide in Acquired Hypothalamic ObesityPHASE3 · ACTIVE_NOT_RECRUITING · started Apr 26, 2023ClinicalTrials.gov NCT05774756 · fetched Nov 12, 2026
- Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityPHASE3 · COMPLETED · started Mar 8, 2022ClinicalTrials.gov NCT04966741 · fetched Nov 12, 2026
- Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayPHASE3 · COMPLETED · started Dec 21, 2021ClinicalTrials.gov NCT05194124 · fetched Nov 12, 2026
- EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayPHASE3 · COMPLETED · started Dec 10, 2021ClinicalTrials.gov NCT05093634 · fetched Nov 12, 2026
- DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayPHASE2 · COMPLETED · started Nov 30, 2021ClinicalTrials.gov NCT04963231 · fetched Nov 12, 2026
- Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy ParticipantsPHASE4 · COMPLETED · started Aug 5, 2021ClinicalTrials.gov NCT05046132 · fetched Nov 12, 2026
- Open-Label Study of Setmelanotide in Hypothalamic ObesityPHASE2 · COMPLETED · started Jun 7, 2021ClinicalTrials.gov NCT04725240 · fetched Nov 12, 2026
- A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal ImpairmentPHASE1 · COMPLETED · started Jul 9, 2020ClinicalTrials.gov NCT04348175 · fetched Nov 12, 2026
- Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityPHASE3 · COMPLETED · started Nov 23, 2018ClinicalTrials.gov NCT03746522 · fetched Nov 12, 2026
- Long Term Extension Trial of SetmelanotidePHASE2_PHASE3 · COMPLETED · started Jul 15, 2018ClinicalTrials.gov NCT03651765 · fetched Nov 12, 2026
- The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) RegistryCOMPLETED · started Apr 15, 2018ClinicalTrials.gov NCT03479437 · fetched Nov 12, 2026
- Setmelanotide in a Single Patient With Partial LipodystrophyPHASE2 · COMPLETED · started Aug 15, 2017ClinicalTrials.gov NCT03262610 · fetched Nov 12, 2026
- Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityPHASE3 · COMPLETED · started Feb 14, 2017ClinicalTrials.gov NCT02896192 · fetched Nov 12, 2026
- Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityPHASE2 · COMPLETED · started Feb 10, 2017ClinicalTrials.gov NCT03013543 · fetched Nov 12, 2026
- Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult VolunteersCOMPLETED · started Sep 28, 2016ClinicalTrials.gov NCT02849977 · fetched Nov 12, 2026
- Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromePHASE2 · COMPLETED · started Mar 19, 2015ClinicalTrials.gov NCT02311673 · fetched Nov 12, 2026
- Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsPHASE1_PHASE2 · COMPLETED · started Jan 1, 2014ClinicalTrials.gov NCT02041195 · fetched Nov 12, 2026
- Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsPHASE2 · COMPLETED · started Jan 14, 2013ClinicalTrials.gov NCT01749137 · fetched Nov 12, 2026
SEC filings12
- 10-Q · 10-QSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Nov 3, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Aug 4, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 25, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Jun 15, 2026 · fetched Nov 12, 2026
- 10-Q · 10-QSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed May 5, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Apr 3, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 26, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 20, 2026 · fetched Nov 12, 2026
- 8-K · 8-KSEC EDGAR · filed Mar 16, 2026 · fetched Nov 12, 2026